Core Insights - Enphase Energy has announced the initial shipments of the IQ Battery 10C, which is designed to meet the growing demand in the third-party ownership (TPO) market and includes domestically sourced components to qualify for federal tax credits [1][2]. Group 1: Product Launch and Features - The IQ Battery 10C meets the current 45% U.S.-sourced materials threshold for tax credits, with future thresholds of 50% in 2026 and 55% in 2027 anticipated [2]. - The battery has been added to approved vendor lists for several major TPO providers, allowing companies to capture significant tax credit value [2][3]. - The new battery system is part of Enphase's 4th-generation battery launch, which includes the IQ Meter Collar and IQ Combiner 6C, enhancing its functionality as a whole-home backup solution [4][5]. Group 2: Market Impact and Industry Trends - The shift towards third-party owned financing in the energy sector emphasizes the importance of reliable batteries that qualify for domestic content [4]. - The introduction of the IQ Battery 10C aligns with the industry's trend towards leases and power purchase agreements (PPAs), helping installers and developers maximize tax credit opportunities [5]. - Enphase's commitment to building high-performance, incentive-eligible energy systems in the U.S. strengthens its domestic supply chain and competitive position in the market [5]. Group 3: Company Background - Enphase Energy is a leading global energy technology company based in Fremont, CA, specializing in microinverter-based solar and battery systems [7]. - The company has shipped approximately 83.1 million microinverters and deployed over 4.9 million Enphase-based systems in more than 160 countries [7].

Company Overview - Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on developing gene therapies for inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders [3] - The company's pipeline includes AAV-based gene therapies targeting conditions such as Leber congenital amaurosis (LCA), bestrophinopathy, and retinitis pigmentosa [3] - Lead gene therapy candidates include OPGx-LCA5, currently in a Phase 1/2 trial for LCA5-related mutations, and OPGx-BEST1 for BEST1-related retinal degeneration [3] - Additionally, the company is advancing Phentolamine Ophthalmic Solution 0.75%, which is approved for one indication and is being studied in two Phase 3 programs for presbyopia and low light vision disturbances [3] Upcoming Presentations - Opus Genetics will present its IRD gene therapy programs at several scientific conferences in September 2025 [1] - Presentation at the Ophthalmology Futures Forum will focus on "Gene & Cell Therapies for Rare & Common Retinal Diseases: Hype Vs Progress" on September 3, 2025 [2] - At the RD 2025 International Symposium, the company will share one-year results from a Phase I/II study of OPGx-LCA5 for inherited retinal degeneration due to biallelic mutations in the LCA5 gene [2] - The LSX World Congress will feature a presentation titled "The Equation for Maturation: Biotech Requirements to Achieve Scale" [2] Key Personnel - Sally Tucker, Ph.D., Senior Vice President Clinical Development, will present at the Ophthalmology Futures Forum and participate in a panel discussion in Paris, France on September 3, 2025 [4] - Ash Jayagopal, Ph.D., Chief Scientific & Development Officer, will present in Prague, Czech Republic on September 15, 2025 [4] - Ben Yerxa, Ph.D., President, will also participate in a panel discussion in Boston, MA on September 17, 2025 [4]

SEATTLE, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the following investor conferences. Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NYManagement is scheduled to participate in a fireside chat on Monday, September 8h at 10:50 a.m. Pacific Time / 1:50 p.m. Eastern Time. Q3 Investor Summit Group Virtual ConferenceManag ...

Group 1 - Soleno Therapeutics, Inc. will participate in several investor conferences in September 2025, including the Cantor Global Healthcare Conference and Wells Fargo Healthcare Conference [1] - The presentation format for all listed conferences will be a fireside chat, allowing for an interactive discussion [1] - Replays of the Cantor and Wells Fargo events will be available on the company's website for investors [1] Group 2 - Soleno Therapeutics focuses on developing and commercializing novel therapeutics for rare diseases [2] - The company's first commercial product, VYKAT™ XR, is an oral treatment for hyperphagia in individuals with Prader-Willi syndrome, available for adults and children aged 4 and older [2] - For further information, the company provides resources on its website [2]

Company Overview - Blade Air Mobility, Inc. is changing its legal name to Strata Critical Medical, Inc. to focus on mission-critical logistics and medical services for hospitals and healthcare providers [1][2] - The company is one of the largest transporters of human organs for transplant in the United States and provides air transportation and logistics services primarily in the Northeast United States, Southern Europe, and Western Canada [3] Stock Information - The name change will take effect on August 28, 2025, and the company's common stock will begin trading under the symbol "SRTA" on August 29, 2025 [2] - The CUSIP numbers for the company's common stock and warrants will remain unchanged, and no action is required from securityholders [2] Business Model - Blade operates an asset-light model with exclusive passenger terminal infrastructure and proprietary technologies, facilitating a transition to Electric Vertical Aircraft (EVA or eVTOL) for lower-cost, quiet, and emission-free air mobility [3]

Core Viewpoint - Slide Insurance Holdings, Inc. has authorized a stock repurchase program of up to $75 million, reflecting confidence in its strategic direction and financial health [1][2]. Company Overview - Slide is a technology-enabled insurance company focused on optimizing the insurance process for homeowners using artificial intelligence and big data [5]. Financial Position - The company has a robust balance sheet following its recent IPO and has reported better than expected net margins, indicating a strong capital position [2]. - The stock repurchase program is intended to enhance return on equity and build long-term value for shareholders [2]. Stock Repurchase Program Details - The repurchase may occur in the open market or through privately negotiated transactions, with management determining the timing and amount based on various factors [2]. - The program is flexible, allowing for modifications or suspension at any time without prior notice [2].

Core Insights - Harmonic is set to showcase innovative broadband solutions at SCTE TechExpo25, focusing on enabling fiber-grade multi-gigabit connectivity and enhancing subscriber experiences [1][2] Group 1: Innovations in Broadband Technology - The company is introducing Unified DOCSIS 4.0, which supports both Full Duplex (FDX) and Frequency Division Duplex (FDD) technologies, allowing for ultra-high-capacity throughput and significant cost savings for operators [3] - Harmonic's cOS broadband platform, along with devices like Pearl R-OLT and Jetty remote switch, facilitates a transition from GPON to XGS-PON and up to 100G PON, addressing the demand for high-speed fiber service delivery [4] - The new AI Assistant capability in cOS Central enables smarter, self-healing networks, improving network reliability and subscriber satisfaction while reducing operating costs [5] Group 2: Enhancing User Experience - Harmonic's cOS platform features L4S capabilities that provide ultra-low-lag experiences, crucial for latency-sensitive applications such as online gaming and video conferencing [6] - The SeaStar™ optical node allows for rapid deployment of fiber-grade connectivity in lower-density MDUs, reducing capital expenses and enabling revenue expansion for operators [7] Group 3: Industry Engagement and Expertise - Harmonic will share insights on broadband trends and strategies at SCTE TechExpo25, highlighting its cOS platform's role in powering next-gen broadband services for over 35 million CPE devices globally [8] - Key executives from Harmonic will participate in various sessions at the expo, discussing topics such as next-gen networks, AI in broadband operations, and the future of FTTx [12]

ARLINGTON, Va., Aug. 27, 2025 /PRNewswire/ -- RTX (NYSE: RTX) Chairman and CEO Chris Calio will speak at the Morgan Stanley 13th Annual Laguna Conference on Wednesday, Sept. 10 at 11:30 a.m. Eastern Time. The presentation will be broadcast live at www.rtx.com and will be archived on the website afterward. Media Contact C: 202.384.2474 Investor Contact C: 781.522.5123 SOURCE RTX About RTX RTX is the world's largest aerospace and defense company. With more than 185,000 global employees, we push the limits of ...

FDA Establishes April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Comprehensive Data Package Supported by Positive Results from Phase 3 STRIVE-ON Safety Trial of GTx-104 PRINCETON, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulatio ...

CARLSBAD, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat at the 2025 Cantor Global Healthcare Conference on Thursday, September 4, 2025, at 10:55 a.m. ET in New York. A live webcast of the fireside chat will be available here and in the investors section of the company’s website at www.designtx.com. Th ...